Joseph Dal Porto

Joseph Dal Porto was appointed Chief Scientific Officer of Second Genome in January 2022. Before coming to Second Genome, Joe served as a Vice President in Pfizer’s Emerging Science & Innovation division and Site Head for Pfizer’s Centers for Therapeutic Innovation (CTI) – West Coast, where his research focused on rapid translational drug development through academic-industry collaborations. At CTI, Joe directed the application of biopharmaceutical know-how and technology to bring ground-breaking scientific innovations to the clinic in multiple therapeutic areas. Prior to Pfizer, Joe was cofounder and Director of Preclinical Research and Development at Modus BioMedicine, a biotherapeutics company exploring therapeutic modulation and inhibition of immune cells in disease. This company was a spin-out from his previous position as a Principal Scientist with Roche Palo Alto, where he supervised in vivo pharmacology activities in support of small and large molecule programs and was part of the Translational Clinical Biomarker team for Roche/Genentech’s CD20 franchise (Rituxanâ, Ocrevusâ, and Gazyvaâ). Joe received a BS in Biochemistry from The Johns Hopkins University and has a PhD in Microbiology and Immunology from the University of Maryland, School of Medicine. His postdoctoral training, under an Ares Serano Foundation Fellowship, was conducted at the National Jewish Health Institute in Denver, Colorado and investigated aberrant immunoreceptor signaling in autoimmunity and hematological malignancies.